Good Article17 Jan 2017 14:57
It is estimated that the global mobile health market will be worth $23bn in 2017(1), and it is growing fast: by 2020 it will be worth $61bn(2). Concepta is a key player in this emerging segment having developed a product that focuses on “unexplained infertility” and helping women who suffer from it to conceive.
In just three years, the company has been able to develop an innovative testing platform, obtain product registration and - following a successful listing on the Alternative Investment Market (AIM) on 26th July - is now ready to start commercialisation.
A substantial minority of women struggle to conceive despite many months of trying. And, if doctors cannot find anything physically wrong, these women are usually faced with lengthy periods of worry, insecurity and anxiety. Because they are not typically offered medical assistance until at least a year of trying for a baby unsuccessfully, and aren’t offered IVF until two years have passed, there is a significant period in which these women may feel they aren’t taking enough proactive steps to conceive.
Concepta’s flagship product, MyLotus, measures common issues that can affect a woman’s probability of conception in any given cycle. These issues can vary from cycle to cycle, and when properly accounted for, can reduce the time taken to conceive whereno cause of infertility has been previously identified. MyLotus provides quantitative as well as qualitative results, which is unique for a home fertility test of this kind.
Excitingly, this is only one of many potential future applications for Concepta’s platform. Pharmaceutical companies could use the technology to more effectively monitor patients administering drugs at home – this would be particularly useful as part of clinical trials or to ensure that dosages can be more finely tailored to individual tolerances and requirements.
Likewise, government healthcare representatives should see the value in using this kind of technology to reduce healthcare reliance and hospital admissions by encouraging better health at home. Indeed, indications suggest that in 2017, mobile health could save a total €99bn in healthcare costs in the EU.(3)
The fundamental issues that the Company’s products address are universal and the consumer proposition is unique. Further, a modular manufacturing set-up means flexibility for future applications. Britain’s vote to leave the European Union briefly cast some doubt over the timing of the Company’s float, however this concern was unwarranted and the share issue was oversubscribed. Concepta is at the forefront of a huge growth market within consumer healthcare, and through its clear route to market and the potential for its technology, the investment case is clear to see.
Cambridge Network Limited is a company registered in England under company No. 3400152
The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT
Sign In
Follow the stocks
